following a full submission:
vortioxetine 5mg, 10mg, 20mg film-coated tablet (Brintellix®) is accepted for restricted use within NHS Scotland.
Indication under review: the treatment of major depressive episodes in adults.
SMC restriction: patients who have experienced an inadequate response (either due to lack of adequate efficacy and/or safety concerns/intolerability) to two or more previous antidepressants.
In two phase III, randomised, double-blind studies in adults with major depressive disorder, vortioxetine was non-inferior to two alternative antidepressants at reducing the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 8.
Download detailed advice212KB (PDF)
- Medicine name:
- vortioxetine (Brintellix)
- SMC ID:
- Treatment of major depressive episodes in adults.
- Pharmaceutical company
- Lundbeck Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 11 July 2016